ReviewEuropean heart journal2026
Non-ST-segment elevation acute coronary syndrome: understanding the full spectrum to guide management.
Review in European heart journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Machine learning and traditional regression approaches to predict risk of cardiovascular events in patients with acute coronary syndrome.BMC medical informatics and decision making · 2026Observational
- Pericoronary Radiomics Signature for Non-Culprit Lesion Progression and Revascularization Decision in NSTE-ACS.Diagnostics (Basel, Switzerland) · 2026Article
- Combined assessment of fibrinogen-to-platelet ratio and ApoB/ApoA1 ratio for pre-angiographic risk stratification of severe multivessel coronary disease in NSTEMI.Frontiers in cardiovascular medicine · 2026Article
- Reciprocal mediation of immuno-inflammation and insulin resistance in the risk of chronic kidney disease among patients with coronary artery disease: insights from neutrophil-to-lymphocyte ratio and triglyceride-glucose index.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Acute coronary syndromes are caused by obstructive coronary thrombosis complicating myocardial ischaemic disease and are dichotomously classified according to their electrocardiographic presentation as ST-segment elevation myocardial infraction or non-ST-segment elevation acute coronary syndrome, either without or with elevated myocardial necrosis markers. Initial diagnosis and risk stratification are reliably guided by symptoms, electrocardiographic changes, and troponin elevation and require exclusion of alternative conditions, such as Type 2 myocardial infarction and myocardial injury due to systemic conditions. Timely coronary angiography is a key component of the initial diagnosis to assess the presence of occlusive coronary artery disease, rather than an myocardial infarction with non-occluded coronary arteries, and the suitability for revascularization. While clinical trials with randomization prior to angiography have shown reduction in recurrent myocardial infarction and urgent revascularization with a neutral effect on mortality from an early invasive approach, increased revascularization rates have been systematically associated with reduced mortality in registries and administrative databases. Complete revascularization in patients with multivessel disease has been shown to reduce mortality compared with culprit-only revascularization. The safety of this approach has been shown even in fragile, elderly, and multimorbid patients. Post-acute treatment should be focused on patient-tailored antithrombotic therapy and disease-modifying secondary prevention approaches. This review describes the complex spectrum of non-ST-segment elevation acute coronary syndrome and the importance of complete clinical and coronary angiographic assessment for optimal patient-centred treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.